Insulin polysialic - Xenetic Biosciences

Drug Profile

Insulin polysialic - Xenetic Biosciences

Alternative Names: Polysialic insulin - Xenetic Biosciences; Polysialylated insulin - Xenetic/Synbio; Recombinant human insulin - Xenetic Biosciences; SuliXen; SYN20090110RU; SYN20090510RU

Latest Information Update: 08 Mar 2016

Price : $50

At a glance

  • Originator Lipoxen Technologies
  • Developer SynBio; Xenetic Biosciences
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Small interfering RNA
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported CNS disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Jun 2013 Phase-I clinical trials in CNS disorders in Russia (SC)
  • 08 Sep 2011 Lipoxen is now called Xenetic Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top